2025年3月12日周三，Lexicon制药（NASDAQ: LXRX）在2025年Leerink全球医疗保健大会上发表演讲，概述了其战略重点和发展计划。公司重点介绍了在推进其药物管线方面的机遇和挑战，主要集中在糖尿病神经性疼痛、心力衰竭和肥胖治疗领域。

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

Equities research analysts at StockNews.com assumed coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free ...

Lexicon Pharmaceuticals shares are trading lower by 48% Monday morning. The company earlier announced topline results from ...

对Lexicon制药来说，这是充满挑战的一年。公司股价跌至52周新低，交易价格为$0.39，市值为2.53亿美元。根据 InvestingPro ...

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. | Lexicon Pharmaceuticals ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) has received a consensus rating of “Hold” from the five ratings ...

The company has chosen to move ahead to Phase III trials with its 10mg dose after it saw a 1.74-point reduction in pain score ...

Lexicon Pharmaceuticals Inc (LXRX) reports increased cash reserves, strategic partnerships, and ongoing clinical progress ...

Q4 2024 Earnings Call Transcript March 6, 2025 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0 ...

The Lexicon Easter Treats Giving Box is set to return to Bracknell. The initiative, which runs from March 11 to April 6, 2025, aims to support families in the borough through Bracknell Foodbank and ...

Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into ...